Li C , Yang Z , Li Z , Ma Y , Zhang L , Zheng C , Qiu W , Wu X , Wang X , Li H , Tang J , Qian M , Li D , Wang P , Luo J , Liu M
J Bone Miner Res.2010 Sep 2 ; ():.
PMID: 20814972[PubMed - as supplied by publisher]
Activation of NF-kappaB and MAPKs/AP-1 signaling pathways by receptor activator NF-kappaB ligand (RANKL) is essential for osteoclast activities. Targeting NF-kappaB and MAPKs/AP-1 signaling to modulate osteoclast activities has been a promising strategy for osteoclast related diseases. In this study, we examined the effects of maslinic acid (MA), a pentacyclic triterpene acid which is widely present in dietary plants, on RANKL-induced osteoclastogenesis, osteoclast function, and signaling pathways by in vitro and in vivo assay systems. In mouse bone marrow monocytes (BMMs) and RAW264.7 cells, MA inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner within non-growth inhibitory concentration and MA decreased osteoclastogenesis-related marker gene expression, including TRAP, MMP-9, c-Src, CTR, and cathepsin K. Specifically, MA suppressed osteoclastogenesis and actin-ring formation at early stage. In ovariectomized mice, administration of MA prevented ovariectomy-induced bone loss by inhibiting osteoclast activities. At molecular levels, MA abrogated the phosphorylation of MAPKs and AP-1 activity, inhibited the IkappaBalpha phosphorylation and degradation, blocked NF-kappaB/p65 phosphorylation, nuclear translocation, and DNA binding activity by down-regulating RANK expression and blocking RANK interaction with TRAF6. Together, our data demonstrate that MA suppresses RANKL-induced osteoclastogenesis through NF-kappaB and MAPKs/AP-1 signaling pathways and MA is a promising agent in the treatment of osteoclast related diseases, such as osteoporosis. (c) 2010 American Society for Bone and Mineral Research.